Rituximab-induced autoimmune hepatitis: A case study and literature review.

MALT lymphoma autoimmune hepatitis drug-induced liver injury idiopathic drug-induced liver injury necro-inflammatory hepatitis rituximab

Journal

Canadian liver journal
ISSN: 2561-4444
Titre abrégé: Can Liver J
Pays: Canada
ID NLM: 101778326

Informations de publication

Date de publication:
2020
Historique:
received: 26 04 2020
accepted: 08 06 2020
entrez: 22 8 2022
pubmed: 17 11 2020
medline: 17 11 2020
Statut: epublish

Résumé

Rituximab is a monoclonal antibody to CD20, often used to treat B-cell lymphomas and various autoimmune diseases. While there is extensive literature on rituximab-induced liver injury related to hepatitis B reactivation, there have been no reports to date of autoimmune-type idiopathic drug-induced liver injury from this drug. We present a case of necro-inflammatory hepatitis with autoimmune features in a 40-year-old female after receiving a second dose of rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma, with a review of the literature.

Identifiants

pubmed: 35990507
doi: 10.3138/canlivj-2020-0009
pmc: PMC9202740
doi:

Types de publication

Case Reports

Langues

eng

Pagination

381-386

Informations de copyright

Copyright © 2020 Canadian Association for the Study of the Liver.

Déclaration de conflit d'intérêts

The authors have nothing to declare.

Références

Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20
pubmed: 23419359
Cancer Biother Radiopharm. 2010 Dec;25(6):747-8
pubmed: 21204770
Clin Med (Lond). 2016 Dec;16(Suppl 6):s104-s109
pubmed: 27956449
JHEP Rep. 2019 Nov 05;1(6):437-445
pubmed: 32039395
Semin Liver Dis. 2014 May;34(2):194-204
pubmed: 24879983
Eur Rev Med Pharmacol Sci. 2017 Mar;21(1 Suppl):112-121
pubmed: 28379588
JAAD Case Rep. 2020 Jan 16;6(2):83-85
pubmed: 31970283
Hepatology. 2009 Jun;49(6):2001-9
pubmed: 19475693
J Hepatol. 2015 Aug;63(2):503-14
pubmed: 25912521
Dig Liver Dis. 2014 Dec;46(12):1116-20
pubmed: 25224696
Sci Rep. 2020 Feb 12;10(1):2456
pubmed: 32051458
Gastroenterology. 2015 Jun;148(7):1340-52.e7
pubmed: 25754159
Transpl Infect Dis. 2020 Feb;22(1):e13211
pubmed: 31713932
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
J Hepatol. 2013 Mar;58(3):529-34
pubmed: 23178709
J Viral Hepat. 2020 Jul;27(7):739-746
pubmed: 32057171
PeerJ. 2019 Sep 09;7:e7481
pubmed: 31565551
Dig Dis Sci. 2011 Nov;56(11):3386-8
pubmed: 21597977
World J Gastroenterol. 2010 Feb 28;16(8):934-47
pubmed: 20180231
Intern Med. 2020 May 1;59(9):1163-1166
pubmed: 31956202

Auteurs

Polymnia Galiatsatos (P)

Division of Gastroenterology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Sarit Assouline (S)

Division of Hematology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Adrian Gologan (A)

Department of Pathology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Nir Hilzenrat (N)

Division of Gastroenterology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Classifications MeSH